| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
In the present study, we got several important findings about the property of CML stem/progenitor cells. First, the frequencies of BCR-ABL positive clone in CD34+CD38- stem cell fraction varied from only 1% to 100% at diagnosis, suggesting that CML stem cells do not necessarily outgrow normal stem cells. On the other hand, the common myeloid progenitor (CMP) fraction markedly expanded in all cases, and the majority of these cells were positive for BCR-ABL FISH, indicating that the growth advantage of CML clone is obtained at the CMP stage. Importantly, leukemic CMPs suppressed the expression of IRF8, a transcription factor in the granulocyte lineage, which might play some role in the cell proliferation. The frequencies of BCR-ABL positive clone in the stem cell fraction strongly correlated with Sokal scores and, more interestingly, with the numbers of megakaryocyte progenitors, suggesting that “megakaryocyte niche” play some role in the survival and self-renewal of CML stem cells.
|
